EICHOR
● Active Not Recruiting
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
Condition: Ovarian Epithelial Cancer Recurrent · Sponsor: UNICANCER
About this study
CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10% failure, an overall number of 444 patients is required.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (33)
| Institut Jules Bordet | Brussels, Belgium | — |
| CHU d'AMIENS | Amiens, France | — |
| Centre Paul Papin | Angers, France | — |
| Institut Bergonie | Bordeaux, France | — |
| Clinique Pasteur | Brest, France | — |
| Polyclinique Kéraudren | Brest, France | — |
| Centre Francois Baclesse | Caen, France | — |
| Centre Jean Perrin | Clermont-Ferrand, France | — |
| Centre hospitalier de Dijon | Dijon, France | — |
| CHU de Grenoble | Grenoble, France | — |
| Clinique Victor Hugo | Le Mans, France | — |
| Pôle Santé Sud | Le Mans, France | — |
+ 21 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01376752